SGMO
Income statement / Annual
Last year (2023), Sangamo Therapeutics, Inc.'s total revenue was $176.23 M,
an increase of 58.34% from the previous year.
In 2023, Sangamo Therapeutics, Inc.'s net income was -$257.83 M.
See Sangamo Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$176.23 M
|
$111.30 M
|
$110.70 M
|
$118.19 M
|
$102.43 M
|
$84.45 M
|
$36.57 M
|
$19.39 M
|
$39.54 M
|
$45.87 M
|
| Cost of Revenue |
$221.56 M |
$12.11 M |
$9.44 M |
$180.65 M |
$145.92 M |
$114.87 M |
$65.73 M |
$65.62 M |
$67.13 M |
$56.74 M |
| Gross Profit |
-$45.33 M |
$99.19 M |
$101.26 M |
-$62.46 M |
-$43.49 M |
-$30.41 M |
-$29.16 M |
-$46.23 M |
-$27.59 M |
-$10.87 M |
| Gross Profit Ratio |
-0.26 |
0.89 |
0.91 |
-0.53 |
-0.42 |
-0.36 |
-0.8 |
-2.38 |
-0.7 |
-0.24 |
| Research and Development
Expenses |
$234.06 M
|
$249.90 M
|
$230.82 M
|
$180.65 M
|
$145.92 M
|
$114.87 M
|
$65.73 M
|
$65.62 M
|
$67.20 M
|
$56.74 M
|
| General & Administrative
Expenses |
$61.17 M
|
$62.68 M
|
$63.22 M
|
$67.10 M
|
$61.69 M
|
$46.74 M
|
$27.20 M
|
$26.33 M
|
$19.20 M
|
$15.68 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$61.17 M
|
$62.68 M
|
$63.22 M
|
$67.10 M
|
$61.69 M
|
$46.74 M
|
$27.20 M
|
$26.33 M
|
$19.20 M
|
$15.68 M
|
| Other Expenses |
-$66.54 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$887,000.00 |
$431,000.00 |
$364,000.00 |
| Operating Expenses |
$228.68 M |
$312.58 M |
$294.04 M |
$247.74 M |
$207.61 M |
$161.60 M |
$92.93 M |
$91.95 M |
$86.40 M |
$72.42 M |
| Cost And Expenses |
$450.24 M |
$312.58 M |
$294.04 M |
$247.74 M |
$207.61 M |
$161.60 M |
$92.93 M |
$91.95 M |
$86.40 M |
$72.42 M |
| Interest Income |
$11.10 M |
$9.43 M |
$5.35 M |
$8.78 M |
$9.76 M |
$8.26 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$22.19 M
|
$12.11 M
|
$9.44 M
|
$5.68 M
|
$3.93 M
|
$2.36 M
|
$1.50 M
|
$997,000.00
|
$988,000.00
|
$549,000.00
|
| EBITDA |
-$87.43 M
|
-$189.17 M
|
-$173.90 M
|
-$123.87 M
|
-$101.25 M
|
-$74.79 M
|
-$54.86 M
|
-$70.68 M
|
-$45.80 M
|
-$26.23 M
|
| EBITDA Ratio |
-0.5 |
-1.81 |
-1.66 |
-1.1 |
-1.03 |
-0.91 |
-1.54 |
-3.74 |
-1.19 |
-0.57 |
| Operating Income Ratio
|
-1.55
|
-1.81
|
-1.66
|
-1.1
|
-1.03
|
-0.91
|
-1.54
|
-3.74
|
-1.19
|
-0.58
|
| Total Other
Income/Expenses Net |
$11.10 M
|
$9.43 M
|
$5.35 M
|
$8.78 M
|
$9.76 M
|
$8.26 M
|
$1.79 M
|
$887,000.00
|
$431,000.00
|
$364,000.00
|
| Income Before Tax |
-$262.90 M |
-$191.85 M |
-$177.99 M |
-$120.78 M |
-$95.42 M |
-$68.89 M |
-$54.57 M |
-$71.67 M |
-$46.43 M |
-$26.42 M |
| Income Before Tax Ratio
|
-1.49
|
-1.72
|
-1.61
|
-1.02
|
-0.93
|
-0.82
|
-1.49
|
-3.7
|
-1.17
|
-0.58
|
| Income Tax Expense |
-$5.07 M |
$429,000.00 |
$306,000.00 |
$345,000.00 |
-$19.60 M |
$8.26 M |
-$1.50 M |
-$14,000.00 |
-$5.72 M |
-$683,000.00 |
| Net Income |
-$257.83 M |
-$192.28 M |
-$178.30 M |
-$121.12 M |
-$75.82 M |
-$68.33 M |
-$54.57 M |
-$71.66 M |
-$40.70 M |
-$26.42 M |
| Net Income Ratio |
-1.46 |
-1.73 |
-1.61 |
-1.02 |
-0.74 |
-0.81 |
-1.49 |
-3.7 |
-1.03 |
-0.58 |
| EPS |
-1.48 |
-1.25 |
-1.23 |
-0.9 |
-0.68 |
-0.7 |
-0.7 |
-1.02 |
-0.58 |
-0.39 |
| EPS Diluted |
-1.48 |
-1.25 |
-1.23 |
-0.9 |
-0.68 |
-0.7 |
-0.7 |
-1.02 |
-0.58 |
-0.39 |
| Weighted Average Shares
Out |
$174.44 M
|
$154.35 M
|
$144.57 M
|
$134.45 M
|
$112.11 M
|
$96.94 M
|
$78.08 M
|
$70.55 M
|
$69.76 M
|
$67.02 M
|
| Weighted Average Shares
Out Diluted |
$174.44 M
|
$154.35 M
|
$144.57 M
|
$134.45 M
|
$112.11 M
|
$96.94 M
|
$78.08 M
|
$70.55 M
|
$69.76 M
|
$67.02 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
